NAMS
The table below shows NewAmsterdam Pharma Company N.V.'s balance sheet line items across its last 3 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Cash & equivalents | $490.00M | $771.74M | - |
| Short-term investments | $146.24M | $62.45M | - |
| Receivables | - | - | - |
| Inventory | - | - | - |
| Total current assets | $675.70M | $863.41M | $346.79M |
| Property, plant & equipment | $383.00K | $242.00K | $46.00K |
| Goodwill | - | - | - |
| Total assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $769.28M |
| $864.62M |
| $347.10M |
| Accounts payable | $8.97M | $4.74M | $16.92M |
| Total current liabilities | $85.79M | $106.92M | $49.90M |
| Long-term debt | - | - | - |
| Total liabilities | $85.85M | $107.12M | $58.70M |
| Retained earnings | -$762.39M | -$558.57M | -$316.97M |
| Total equity | $683.43M | $757.50M | $288.39M |